… announced on May 11th 2012. Brewer is an industry veteran who has a long track record of developing successful strategies at better known companies like Roche ( RHHBY.PK ) and Dendreon ( DNDN ). Despite some small problems from Complete Story »
… Investment Management : Without a doubt, Dendreon ( DNDN ) is one of the most controversial stocks ..... cancer market. Over the past year, Dendreon has suffered mightily, with the stock ..... could things finally be looking up for Dendreon ? The market will soon be able to get …
… considered biotech's immunotherapy darling, shares of Dendreon Corporation ( DNDN ) have been taking a beating. Does this mean the ..... Sell" warning and a lowly $5 price target. " Dendreon is a pioneer in the cancer field, delivering the …
Shares of Dendreon ( DNDN -5.1% ) continue their descent today after Maxim initiates coverage with a sell rating, saying that Provenge faces logistic, manufacturing and competitive challenges that could impede sales growth. 1 comment!
By Theodore Cohen: Dendreon ( DNDN ) is a difficult stock to own ... ask anyone who is or was a shareholder. The history of this company and its travails with …
By Theodore Cohen: On Wednesday, May 16, Dendreon Corporation ( DNDN ) announced four presentations to be given at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, taking …
Dendreon Corporation ( DNDN ) Bank of America Merrill Lynch 2012 Health Care Conference May 16 ..... Lynch. And it’s my pleasure to introduce Greg Schiffman, CFO of Dendreon with the latest update. Thanks. Greg Schiffman Thanks very much …
Shares of Dendreon ( DNDN ) are trading lower after hours on unconfirmed rumors that the SEC has opened a probe on the company's disclosures. While the …
… engineer it to develop their own wares from it to benefit them and their potential customer base with their own "new" product. Dendreon received the FDA's approval to market Provenge in April of 2010 for asymptomatic or minimally symptomatic hormone-refractory …
… of live surgeries, and a host of other activities of importance to the urological community. Of particular interest to Dendreon ( DNDN ) investors are two papers to be presented on the corporation's lead immunotherapeutic treatment for end stage prostate …